Skip to main content
Top
Published in: Journal of General Internal Medicine 5/2013

Open Access 01-05-2013 | Original Research

Independent Contribution of A1C, Systolic Blood Pressure, and LDL Cholesterol Control to Risk of Cardiovascular Disease Hospitalizations in Type 2 Diabetes: An Observational Cohort Study

Authors: Gregory A. Nichols, PhD, Sandra Joshua-Gotlib, MSPH, MBA, Shreekant Parasuraman, PhD

Published in: Journal of General Internal Medicine | Issue 5/2013

Login to get access

ABSTRACT

BACKGROUND

Cardiovascular disease (CVD) prevention in diabetes requires broad-based treatment of dyslipidemia, hypertension, and hyperglycemia. The independent contribution of all combinations of risk factor control to CVD risk has not been evaluated.

OBJECTIVE

To estimate the independent association of control of glycosylated hemoglobin (A1C), systolic blood pressure (SBP), and low-density lipoprotein cholesterol (LDL-C) with risk of cardiovascular disease hospitalization.

DESIGN

Non-concurrent longitudinal cohort study.

PATIENTS

The study included 26,636 patients with type 2 diabetes who were members of an integrated group model HMO with multiple A1C, SBP, and LDL-C measurements.

MAIN MEASURES

Patients were followed for a mean (SD) of 5.6 (2.5) years until they died or disenrolled, or until 31 December 2010. The outcome was a first-observed CVD hospitalization. Using the mean of all A1C, SBP, and LDL-C measures during follow-up, we created dichotomous categories of A1C control (< 7 %), SBP control (< 130 mmHg), and LDL-C control (< 100 mg/dL) to estimate the incidence rate of CVD hospitalization associated with all combinations of risk factor control adjusting for demographic and clinical characteristics.

KEY RESULTS

Patients with no controlled risk factors (18.2/1,000 person-years, 95 % CI 16.5−20.2) or with only A1C in control (16.9, 15.0−19.0) had the highest rate of CVD hospitalization, whereas those with all three risk factors controlled (7.2, 6.2−8.4) or with SBP and LDL-C in control (6.1, 5.1−7.2) had the lowest rates. Those with only SBP or LDL-C in control, A1C and SBP controlled, or A1C and LDL-C controlled had statistically similar incidence between the highest and lowest rates.

CONCLUSIONS

Maintaining SBP < 130 mmHg or LDL-C < 100 mg/dL was significantly associated with reduced CVD hospitalization risk, especially when both risk factors were well controlled. Maintaining A1C < 7 % was not independently associated with reduced CVD hospitalization risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care. 2012;35(Suppl 1):S11–S63. American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care. 2012;35(Suppl 1):S11–S63.
2.
go back to reference Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.PubMedCrossRef Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.PubMedCrossRef
3.
go back to reference Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.PubMedCrossRef Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.PubMedCrossRef
4.
go back to reference Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.PubMedCrossRef Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.PubMedCrossRef
5.
go back to reference Stratton IM, Alder AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.PubMedCrossRef Stratton IM, Alder AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.PubMedCrossRef
6.
go back to reference Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: a nested case–control study. Diabetes Care. 2011;34(1):77–83.PubMedCrossRef Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: a nested case–control study. Diabetes Care. 2011;34(1):77–83.PubMedCrossRef
7.
go back to reference Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–811.PubMedCrossRef Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–811.PubMedCrossRef
8.
go back to reference Grundy SM, Cleeman JI, Bairey-Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239.PubMedCrossRef Grundy SM, Cleeman JI, Bairey-Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239.PubMedCrossRef
9.
go back to reference National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Working Group report on hypertension in diabetes. Hypertension. 1994;23(2):145–158.CrossRef National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Working Group report on hypertension in diabetes. Hypertension. 1994;23(2):145–158.CrossRef
10.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393.PubMedCrossRef Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393.PubMedCrossRef
11.
go back to reference Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–172.PubMedCrossRef Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–172.PubMedCrossRef
12.
go back to reference Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes trials. Diabetes Care. 2009;32(1):187–192.PubMedCrossRef Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes trials. Diabetes Care. 2009;32(1):187–192.PubMedCrossRef
13.
go back to reference Stratton IM, Matthews DR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49:1761–1769.PubMedCrossRef Stratton IM, Matthews DR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49:1761–1769.PubMedCrossRef
14.
go back to reference Gudbjornsdotir S, Eliasson B, Eeg-Olofsson K, Zethelius B, Cederholm J. on behalf of the National Diabetes Register (NDR). Additive effoects of glycaemia and dyslipidemia on risk of cardiovascular disease in type 2 diabetes: an observational study from the Swedish National Diabetes Register. Diabetologia. 2011;54:2544–2551.CrossRef Gudbjornsdotir S, Eliasson B, Eeg-Olofsson K, Zethelius B, Cederholm J. on behalf of the National Diabetes Register (NDR). Additive effoects of glycaemia and dyslipidemia on risk of cardiovascular disease in type 2 diabetes: an observational study from the Swedish National Diabetes Register. Diabetologia. 2011;54:2544–2551.CrossRef
15.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–470.PubMedCrossRef Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–470.PubMedCrossRef
16.
go back to reference Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068–2074.PubMedCrossRef Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068–2074.PubMedCrossRef
17.
go back to reference Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Eliasson B, Gudbjornsdottir S, et al. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diab Res Clin Pract. 2009;86:74–81.CrossRef Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Eliasson B, Gudbjornsdottir S, et al. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diab Res Clin Pract. 2009;86:74–81.CrossRef
18.
go back to reference Gaede P, Lund-Anderson H, Parving HH, Pederson O. Effect of a multi-factorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.PubMedCrossRef Gaede P, Lund-Anderson H, Parving HH, Pederson O. Effect of a multi-factorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.PubMedCrossRef
19.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35(6):1364–1379.PubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35(6):1364–1379.PubMedCrossRef
20.
go back to reference UKPDS Group. UKPDS 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet. 1998;352:837–851.CrossRef UKPDS Group. UKPDS 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet. 1998;352:837–851.CrossRef
21.
go back to reference Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430.PubMedCrossRef Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430.PubMedCrossRef
22.
go back to reference Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdotir S, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study for the Swedish National Diabetes Register (NDR). J Intern Med. 2010;268(5):471–482.PubMedCrossRef Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdotir S, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study for the Swedish National Diabetes Register (NDR). J Intern Med. 2010;268(5):471–482.PubMedCrossRef
23.
go back to reference Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with type 2 diabetes: a large prospective cohort study. Diabet Med. 2008;25:1295–1301.PubMed Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with type 2 diabetes: a large prospective cohort study. Diabet Med. 2008;25:1295–1301.PubMed
24.
go back to reference Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481–489.PubMedCrossRef Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481–489.PubMedCrossRef
25.
go back to reference Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55(3):636–643.PubMedCrossRef Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55(3):636–643.PubMedCrossRef
26.
go back to reference Jorgensen CH, Gislason GH, Bretler D, Sorensen R, Norgaard ML, Hansen ML, et al. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction—A nationwide study. Int J Cardiol. 2011;152(3):327–331.PubMedCrossRef Jorgensen CH, Gislason GH, Bretler D, Sorensen R, Norgaard ML, Hansen ML, et al. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction—A nationwide study. Int J Cardiol. 2011;152(3):327–331.PubMedCrossRef
27.
go back to reference Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080.PubMedCrossRef Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080.PubMedCrossRef
28.
go back to reference Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2011;57(20):2037-114.PubMedCrossRef Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2011;57(20):2037-114.PubMedCrossRef
29.
go back to reference Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585.PubMedCrossRef Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585.PubMedCrossRef
30.
go back to reference Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61–68.PubMedCrossRef Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61–68.PubMedCrossRef
31.
go back to reference Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing telmisartan alone and in combination with ramipril global endpoint trial). J Am Coll Cardiol. 2012;59(1):74–83.PubMedCrossRef Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing telmisartan alone and in combination with ramipril global endpoint trial). J Am Coll Cardiol. 2012;59(1):74–83.PubMedCrossRef
32.
go back to reference Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117(15):1945–1954.PubMedCrossRef Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117(15):1945–1954.PubMedCrossRef
33.
go back to reference Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512–1524.PubMedCrossRef Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512–1524.PubMedCrossRef
Metadata
Title
Independent Contribution of A1C, Systolic Blood Pressure, and LDL Cholesterol Control to Risk of Cardiovascular Disease Hospitalizations in Type 2 Diabetes: An Observational Cohort Study
Authors
Gregory A. Nichols, PhD
Sandra Joshua-Gotlib, MSPH, MBA
Shreekant Parasuraman, PhD
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 5/2013
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-012-2320-1

Other articles of this Issue 5/2013

Journal of General Internal Medicine 5/2013 Go to the issue